Spots Global Cancer Trial Database for giredestrant
Every month we try and update this database with for giredestrant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer | NCT05634499 | Endometrial Can... | Giredestrant | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | NCT04961996 | Early Breast Ca... | Giredestrant Endocrine Thera... LHRH Agonist Abemaciclib | 18 Years - | Hoffmann-La Roche | |
| A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer | NCT05896566 | Breast Cancer | Giredestrant Triptorelin Anastrozole | 18 Years - | ETOP IBCSG Partners Foundation | |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) | NCT04436744 | Early Breast Ca... | Giredestrant Anastrozole Palbociclib Surgery | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | NCT05296798 | Locally Advance... | Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | NCT04486352 | Endometrial Can... | Atezolizumab - ... Bevacizumab Ipatasertib Talazoparib Trastuzumab emt... Tiragolumab Atezolizumab - ... Inavolisib Letrozole Giredestrant Abemaciclib | 18 Years - | Alliance Foundation Trials, LLC. | |
| A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer) | NCT04546009 | Estrogen Recept... | Giredestrant Giredestrant-ma... Letrozole Letrozole-match... Palbociclib LHRH Agonist | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) | NCT05296798 | Locally Advance... | Phesgo Giredestrant Docetaxel Paclitaxel LHRH Agonist Optional Endocr... | 18 Years - | Hoffmann-La Roche | |
| A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer | NCT05634499 | Endometrial Can... | Giredestrant | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | NCT04802759 | Inoperable, Loc... | Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) | NCT04436744 | Early Breast Ca... | Giredestrant Anastrozole Palbociclib Surgery | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | NCT05306340 | Estrogen Recept... | Giredestrant Exemestane Fulvestrant Tamoxifen Everolimus LHRH Agonist Dexamethasone M... | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) | NCT05306340 | Estrogen Recept... | Giredestrant Exemestane Fulvestrant Tamoxifen Everolimus LHRH Agonist Dexamethasone M... | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors | NCT04931342 | Ovarian Cancer | Ipatasertib Cobimetinib Trastuzumab Emt... Atezolizumab Bevacizumab Paclitaxel Giredestrant Abemaciclib Inavolisib Palbociclib Letrozole Olaparib Luteinizing Hor... Cyclophosphamid... Inavolisib | 18 Years - | Hoffmann-La Roche | |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | NCT06065748 | Estrogen Recept... | Giredestrant Fulvestrant Abemaciclib Palbociclib Ribociclib LHRH Agonist FoundationOne L... | 18 Years - | Hoffmann-La Roche | |
| A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | NCT03916744 | Breast Cancer | Giredestrant Surgery | 18 Years - | Genentech, Inc. | |
| A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer | NCT03916744 | Breast Cancer | Giredestrant Surgery | 18 Years - | Genentech, Inc. | |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | NCT04802759 | Inoperable, Loc... | Giredestrant Abemaciclib Ipatasertib Inavolisib Ribociclib Everolimus Samuraciclib PH FDC SC Palbociclib Atezolizumab | 18 Years - | Hoffmann-La Roche | |
| A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer) | NCT04961996 | Early Breast Ca... | Giredestrant Endocrine Thera... LHRH Agonist Abemaciclib | 18 Years - | Hoffmann-La Roche |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
